



# SAHS & NDOH Hypertension Management Lecture Series


## Back to Basics in Hypertension Management




# SA Hypertension Treatment

## Risk Stratification and Special Investigations


# Regulation of Blood Pressure



# Importance of CV risk







# CVD Risk Factors in HPT

Modifiable Risk Factors*	Relatively Fixed Risk Factors†
<ul style="list-style-type: none"><li>• Current cigarette smoking, secondhand smoking</li><li>• Diabetes mellitus</li><li>• Dyslipidemia/hypercholesterolemia</li><li>• Overweight/obesity</li><li>• Physical inactivity/low fitness</li><li>• Unhealthy diet</li></ul>	<ul style="list-style-type: none"><li>• CKD</li><li>• Family history</li><li>• Increased age</li><li>• Low socioeconomic/educational status</li><li>• Male sex</li><li>• Obstructive sleep apnea</li><li>• Psychosocial stress</li></ul>

# Routine Investigations in Hypertension

<i>Test</i>	<i>Comment</i>
Height, weight, BMI	Ideal BMI < 25 kg/m <sup>2</sup> , overweight 25–30 kg/m <sup>2</sup> , obese > 30 kg/m <sup>2</sup>
Waist circumference	Men < 102 cm; women < 88 cm. South Asians and Chinese: men < 90 cm and women < 80 cm
Electrolytes	Low potassium may indicate primary aldosteronism, or effects of diuretics
ECG	S in V1 plus R in V5 or V6 > 35 mm or R in aVL > 11 mm or Cornell product (R in aVL + S in V3 + 6 in females) × QRS duration > 2 440 (mm/ms)
Echocardiogram (if indicated and facilities available)	LVH: men > 115 g/m <sup>2</sup> and women > 95 g/m <sup>2</sup>
Fasting glucose	Consider HBA <sub>1c</sub> or GTT if impaired fasting glucose (6.1–7.1 mmol/l)
Cholesterol	If total cholesterol > 5.1 mmol/l – fasting lipogram
Creatinine	Calculate eGFR
Uric acid	High uric acid is relative contraindication to diuretics
Dipsticks urine	If abnormal, urine microscopy and protein estimation

# Mandatory Investigations


Investigation	TOD	Secondary cause	Risk stratification
Dipsticks urine	Yes, usually 1+ protein only in hypertensive nephrosclerosis	2+ or more proteinuria and/or haematuria suggests kidney disease	Yes
ECG	LVH (see ECG criteria)	No	Yes
Creatinine/eGFR	Yes	Yes	Yes
Echocardiogram <sup>#</sup>	LVH	No	Yes
K <sup>+</sup>	No	Low K <sup>+</sup> may suggest primary aldosteronism/excess diuretic	No
Fasting glucose	No	No	Yes
Fasting lipogram	No	No	Yes
Urine albumin/creatinine ratio*	Yes	Yes, if markedly elevated	Yes

\*mandatory in diabetics, first voided urine specimen, < 3mg – normal, 3-30 microalbuminuria, > 30 macroalbuminuria (spot urines tend to overestimate ratio),

# - only if readily available



# ECG Criteria for LVH



Electrocardiogram from patient with malignant hypertension. Voltage changes of left ventricular hypertrophy (de

Repolarisation changes  
- harbinger of death

**TABLE: IV: MAJOR RISK FACTORS, TARGET ORGAN DAMAGE (TOD) AND COMPLICATIONS**

MAJOR RISK FACTORS.	TOD	Complications
<ul style="list-style-type: none"> <li>• Levels of systolic and diastolic BP.</li> <li>• Smoking.</li> <li>• Dyslipidaemia:               <ul style="list-style-type: none"> <li>○ total cholesterol &gt; 5.1 mmol/L, <b>OR</b></li> <li>○ LDL &gt; 3 mmol/L, <b>OR</b></li> <li>○ HDL men &lt;1 and women &lt;1.2 mmol/L.</li> </ul> </li> <li>• Diabetes mellitus.</li> <li>• Men &gt; 55 years.</li> <li>• Women &gt; 65 years.</li> <li>• Family history of early onset of CVD:               <ul style="list-style-type: none"> <li>○ Men aged &lt;55 years;</li> <li>○ Women aged &lt;65 years.</li> </ul> </li> <li>• Waist circumference- abdominal obesity:               <ul style="list-style-type: none"> <li>○ Men ≥ 102 cm;</li> <li>○ Women ≥ 88 cm.</li> </ul> <p>The exceptions are South Asians and Chinese: Men: &gt;90 cm and Women: &gt;80 cm.</p> </li> </ul>	<ul style="list-style-type: none"> <li>• LVH: based on ECG               <ul style="list-style-type: none"> <li>○ Sokolow-Lyons &gt;35mm</li> <li>○ R in aVL &gt; 11 mm</li> <li>○ Cornell &gt; 2440 (mm.ms)</li> </ul> </li> <li>• Microalbuminuria:               <p>albumin creatine ratio 3-30 mg/mmol preferably spot morning urine and eGFR &gt; 60ml/min</p> </li> </ul>	<ul style="list-style-type: none"> <li>• Coronary heart disease</li> <li>• Heart failure</li> <li>• Chronic kidney disease:               <ul style="list-style-type: none"> <li>○ macroalbuminuria &gt; 30mg/mmol</li> </ul> <p><b>OR</b> eGFR &lt; 60ml/min</p> </li> <li>• Stroke or TIA</li> <li>• Peripheral arterial disease</li> <li>• Advanced retinopathy:               <ul style="list-style-type: none"> <li>○ haemorrhages <b>OR</b>;</li> <li>○ exudates;</li> <li>○ papilloedema.</li> </ul> </li> </ul>

(Adapted from the ESH/ ESC guidelines) [9]

Risk stratification guides treatment

# Cardiovascular Risk Assessment

<b>Very high risk</b>	<p><b>People with any of the following:</b></p> <p><b>Documented CVD, either clinical or unequivocal on imaging.</b></p> <ul style="list-style-type: none"> <li>• <b>Clinical CVD</b> includes acute myocardial infarction, acute coronary syndrome, coronary or other arterial revascularization, stroke, TIA, aortic aneurysm, and PAD</li> <li>• <b>Unequivocal documented CVD on imaging</b> includes significant plaque (i.e. <math>\geq 50\%</math> stenosis) on angiography or ultrasound; it does not include increase in carotid intima-media thickness</li> <li>• <b>Diabetes mellitus with target organ damage</b>, e.g. proteinuria or a with a major risk factor such as grade 3 hypertension or hypercholesterolaemia</li> <li>• <b>Severe CKD</b> (eGFR <math>&lt; 30</math> mL/min/1.73 m<sup>2</sup>)</li> <li>• <b>A calculated 10 year SCORE of <math>\geq 10\%</math></b></li> </ul>
<b>High risk</b>	<p><b>People with any of the following:</b></p> <ul style="list-style-type: none"> <li>• <b>Marked elevation of a single risk factor</b>, particularly cholesterol <math>&gt; 8</math> mmol/L (<math>&gt; 310</math> mg/dL), e.g. familial hypercholesterolaemia or grade 3 hypertension (BP <math>\geq 180/110</math> mmHg)</li> <li>• <b>Most other people with diabetes mellitus</b> (except some young people with type 1 diabetes mellitus and without major risk factors, who may be at moderate-risk)</li> </ul> <p><b>Hypertensive LVH</b></p> <p><b>Moderate CKD eGFR 30-59 mL/min/1.73 m<sup>2</sup>)</b></p> <p><b>A calculated 10 year SCORE of 5-10%</b></p>
<b>Moderate risk</b>	<p><b>People with:</b></p> <ul style="list-style-type: none"> <li>• <b>A calculated 10 year SCORE of <math>\geq 1</math> to <math>&lt; 5\%</math></b></li> <li>• <b>Grade 2 hypertension</b></li> <li>• <b>Many middle-aged people belong to this category</b></li> </ul>
<b>Low risk</b>	<p><b>People with:</b></p> <ul style="list-style-type: none"> <li>• <b>A calculated 10 year SCORE of <math>&lt; 1\%</math></b></li> </ul>

# Total Cardiovascular Risk Stratification

Hypertension disease staging	Other risk factors, HMOD, or disease	BP (mmHg) grading			
		High normal SBP 130-139 DBP 85-89	Grade 1 SBP 140-159 DBP 90-99	Grade 2 SBP 160-179 DBP 100-109	Grade 3 SBP $\geq 180$ or DBP $\geq 110$
Stage 1 (uncomplicated)	No other risk factors	Low risk	Low risk	Moderate risk	High risk
	1 or 2 risk factors	Low risk	Moderate risk	Moderate to high risk	High risk
	$\geq 3$ risk factors	Low to Moderate risk	Moderate to high risk	High Risk	High risk
Stage 2 (asymptomatic disease)	HMOD, CKD grade 3, or diabetes mellitus without organ damage	Moderate to high risk	High risk	High risk	High to very high risk
Stage 3 (established disease)	Established CVD, CKD grade $\geq 4$ , or diabetes mellitus with organ damage	Very high risk	Very high risk	Very high risk	Very high risk



# Case Study



- Mr. AB, a 54 year old male – blue collar worker
- Metabolic syndrome – hypertensive, dyslipidaemia and type 2 diabetic with central obesity
- Presents to the OPD for his 6 monthly follow-up appointment
- He is on lifestyle & dietary management and taking Medications
- He is a smoker



# Clinical Examination

- Blood pressure – 167/98 mmHg at rest (Office BP reading)
- Pulse rate of 88 beats/min
- Respiratory rate of 18 breaths/min
- Grade 2 Pedal oedema ( Preserved LVEF – Echocardiogram done 6 months ago)
- Normal Heart Sounds
- NYHA Class II




# Medication

- Metformin 850mg po BD, Atorvastatin 40 mg po nocte
- Amlodipine 10mg po daily
- Enalapril 10 mg po daily
- History of sporadic inflammatory arthritis of the small joints of the hand treat with OTC self prescription
- NYHA Class II



# What is this patient's 10 year Cardiovascular Risk?



Know your blood pressure by 

# Framingham 10 Yr. CVD Risk

## Step 1<sup>1</sup>

In the "points" column enter the appropriate value according to the patient's age, HDL-C, total cholesterol, systolic blood pressure, and if they smoke or have diabetes. Calculate the total points.

Risk Factor		Risk Points		Points		
		Men		Women		
Age						
30-34		0		0		
35-39		2		2		
40-44		5		4		
45-49		7		5		
50-54		8		7		
55-59		10		8		
60-64		11		9		
65-69		12		10		
70-74		14		11		
75+		15		12		
HDL-C (mmol/L)						
>1.6		-2		-2		
1.3-1.6		-1		-1		
1.2-1.29		0		0		
0.9-1.19		1		1		
<0.9		2		2		
Total Cholesterol						
<4.1		0		0		
4.1-5.19		1		1		
5.2-6.19		2		3		
6.2-7.2		3		4		
>7.2		4		5		
Systolic Blood Pressure (mmHg)		Not Treated	Treated	Not Treated	Treated	
<120		-2	0	-3	-1	
120-129		0	2	0	2	
130-139		1	3	1	3	
140-149		2	4	2	5	
150-159		2	4	4	6	
160+		3	5	5	7	
Smoker	Yes	4		3		
	No	0		0		
Diabetes	Yes	statin-indicated condition				
	No	0		0		
Total Points						

Adapted from the Canadian Cardiovascular Society

# Framingham 10 Yr. CVD Risk

## Step 2<sup>1</sup>

Using the total points from Step 1, determine the 10-year CVD risk\* (%).

Total Points	10-Year CVD Risk (%)*	
	Men	Women
-3 or less	<1	<1
-2	1.1	<1
-1	1.4	1.0
0	1.6	1.2
1	1.9	1.5
2	2.3	1.7
3	2.8	2.0
4	3.3	2.4
5	3.9	2.8
6	4.7	3.3
7	5.6	3.9
8	6.7	4.5
9	7.9	5.3
10	9.4	6.3
11	11.2	7.3
12	13.3	8.6
13	15.6	10.0
14	18.4	11.7
15	21.6	13.7
16	25.3	15.9
17	29.4	18.51
18	>30	21.5
19	>30	24.8
20	>30	27.5
21+	>30	>30

Adapted from the Canadian Cardiovascular Society



# Framingham 10 Yr. CVD Risk

## Step 3<sup>1</sup>

Using the total points from Step 1, determine heart age (in years).

Heart Age, y	Men	Women
<30	<0	<1
30	0	
31		1
32	1	
34	2	2
36	3	3
38	4	
39		4
40	5	
42	6	5
45	7	6
48	8	7
51	9	8
54	10	
55		9
57	11	
59		10
60	12	
64	13	11
68	14	12
72	15	
73		13
76	16	
79		14
>80	≥17	15+

Adapted from the Canadian Cardiovascular Society

**What other clinical investigations would you perform?**




**SAHS**

*Know your blood pressure by*



# Electrocardiogram



# Monitoring (1)

## At every visit:

- » Weight
- » Blood pressure

## Baseline:

- » Urine protein by dipstix.
  - If dipstix positive send blood for serum creatinine concentration (and eGFR)
- » BMI for cardiovascular risk assessment (See Section 4.1: Prevention of ischaemic heart disease and atherosclerosis).
- » Abdominal circumference.
- » Serum potassium concentration, if on ACE-inhibitor or eGFR < 30 mL/min. (See Section 9.2.2: Type 2 Diabetes Mellitus, Adults).

# Monitoring (2)

## Six monthly:

- » Serum potassium concentration in patients on spironolactone or eGFR < 30 mL/min.

## Annually:

- » Fingerprick blood glucose (see Section 9.2.2: Type 2 Diabetes Mellitus, Adults).
- » Urine protein by dipstix (see Section 8.1: Chronic Kidney Disease (CKD)).
- » Serum creatinine concentration (and eGFR) in patients who have:
  - proteinuria 1+ or more
  - existing cardiovascular disease
  - hypertension present for 10 years or more (annually if uncontrolled)
  - chronic kidney disease (eGFR < 60 mL/min)






A SIMPLE MEASURE TO SAVE LIVES  
#checkyourpressure



## PARTICIPATE IN THE WORLD'S LARGEST FREE PUBLIC BLOOD PRESSURE SCREENING May Measurement Month 2020

- In just 3 years we have already achieved so much!
- **4.2 MILLION+** people have had their blood pressure measured
- In over **100 COUNTRIES**
- Visit <https://www.hypertension.org.za/> to Register





|SAVE THE DATE|  
2021 - Gauteng

# Become a SAHS member

[www.hypertension.org.za](http://www.hypertension.org.za)

